Intelligene, Inc.
Biotechnology company focused on developing siRNA-based therapeutics and RNA delivery systems. The company develops RNA interference (RNAi) drug candidates for infectious diseases (notably COVID-19 and influenza), and operates a GMP pilot plant for formulation, scale-up and manufacturing of lipid nanoparticle (LNP) and engineered exosome delivery systems. It pursues collaborations for clinical development and commercialization.
Industries
N/A
Products
IG-001
siRNA-based therapeutic candidate intended to treat SARS-CoV-2 (COVID-19). Phase I clinical trials were planned to begin in the year referenced in public announcements; development is supported via international collaboration.
IG-002
siRNA-based therapeutic candidate aimed at broad-spectrum influenza treatment; development stage indicated as preclinical or discovery in public materials.
IG-001
siRNA-based therapeutic candidate intended to treat SARS-CoV-2 (COVID-19). Phase I clinical trials were planned to begin in the year referenced in public announcements; development is supported via international collaboration.
IG-002
siRNA-based therapeutic candidate aimed at broad-spectrum influenza treatment; development stage indicated as preclinical or discovery in public materials.
Services
GMP pilot manufacturing and process development
Pilot-scale manufacturing, process development and scale-up services for RNA therapeutics and delivery carriers operating in a GMP-compliant facility.
Custom LNP and exosome formulation and encapsulation
Development and optimization of lipid nanoparticle and engineered exosome formulations to protect and deliver RNA payloads to target tissues.
Preclinical development and clinical trial preparation support
Support for preclinical development and early-phase clinical trial planning, including regulatory and manufacturing strategy through collaborative programs.
GMP pilot manufacturing and process development
Pilot-scale manufacturing, process development and scale-up services for RNA therapeutics and delivery carriers operating in a GMP-compliant facility.
Custom LNP and exosome formulation and encapsulation
Development and optimization of lipid nanoparticle and engineered exosome formulations to protect and deliver RNA payloads to target tissues.
Preclinical development and clinical trial preparation support
Support for preclinical development and early-phase clinical trial planning, including regulatory and manufacturing strategy through collaborative programs.
Expertise Areas
- siRNA therapeutics development
- RNA drug delivery (LNP and exosome carriers)
- Pilot-scale GMP manufacturing and process development
- Formulation and purification for nanoparticle and vesicle carriers
Key Technologies
- siRNA / RNA interference (RNAi)
- Lipid nanoparticles (LNPs)
- Engineered exosomes / extracellular vesicles (EVs)
- Pilot-scale GMP manufacturing